Thermo Fisher Scientific (TMO) EBITDA (2009 - 2026)

Thermo Fisher Scientific (TMO) has reported EBITDA for 18 consecutive years, with $2.1 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBITDA rose 13.79% year-over-year to $2.1 billion; the trailing twelve-month figure through Jun 2026 stood at $8.1 billion (up 10.02% YoY), and the FY2025 full-year result was $7.7 billion, up 5.57% from the prior year.
• EBITDA climbed to $2.1 billion in Q2 2026 per TMO's latest filing, from $1.9 billion in the prior quarter.
• Across five years, EBITDA topped out at $2.8 billion in Q2 2022 and bottomed at $1.6 billion in Q2 2023.
• Historically, EBITDA has averaged $1.9 billion across 5 years, with a median of $1.9 billion in 2022.
• The sharpest annual moves came in 2023 and 2024: EBITDA slumped 44.59% in 2023, then grew 15.34% in 2024.
• Over 5 years, EBITDA stood at $1.9 billion in 2022, then decreased by 0.38% to $1.9 billion in 2023, then rose by 8.74% to $2.0 billion in 2024, then rose by 11.86% to $2.3 billion in 2025, then declined by 7.45% to $2.1 billion in 2026.
• According to Business Quant data, EBITDA over the past three periods registered $2.1 billion, $1.9 billion, and $2.3 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.